Oxazepam

• Catalog No.: DB00842
• CAS Number: 604-75-1
• M. F.: C15H11ClN2O2
• M. W.: 286.71304

SYNONYMS

• IUPAC name: 7-chloro-3-hydroxy-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
• IUPAC Traditional name: oxazepam
• Brand Name: Aplakil; Praxiten; Limbial; Durazepam; Murelax; Lederpam; Astress; Azutranquil; Nesontil; Oxanid; Pacienx; Quilibrex; Seresta; Serpax; Sigacalm; Tazepam; Wy-3498 stic; Adumbran; Ansioxacepam; Anxiolit; Bonare; Drimuel; Droxacepam; Enidrel; Hi-Long; Isodin; Noctazepam; Notaral; Oxa-puren; QUEN; Rondar; Sedigoa; Serenal; Serenid; Serepax; Sobril; Tacepam; Uskan; Propax; Psiquiwas; Serax; Serenid-D; Vaben; Zaxopam
• Synonyms: Oxozepam; d-Oxazepam hemisuccinate; Oxazipam

DATABASE IDS

• PubChem CID: 4616
• PubChem SID: 46506031
• CAS Number: 604-75-1

PROPERTIES

• Hydrophobicity(logP): 2.8
• Solubility: 179 mg/L

DETAILS

Description (English)

• Drug Groups: approved
• Description: Oxazepam is an intermediate-acting benzodiazepine used to treat alcohol withdrawal and anxiety disorders.
• Indication: For the treatment of anxiety disorders and alcohol withdrawal.
• Pharmacology: Oxazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.
• Toxicity: Symptoms of overdose include confusion, drowsiness, and lethargy.
• Affected Organisms: Humans and other mammals
• Biotransformation: No active metabolites. Metabolized via conjugation prior to elimination.
• Absorption: Well absorbed from the gastrointestinal tract following oral administration. Time to peak concentration = 2-4 hours. Onset of action is slow, > 3 hours, following oral administration.
• Half Life: 5-15 hours
• Protein Binding: 80-99%
• Elimination: This product has a single, major inactive metabolite in man, a glucuronide excreted in the urine.
• References: Peppers MP: Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996 Jan-Feb;16(1):49-57. [Pubmed] ; Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [Pubmed] ; Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [Pubmed] ; Christensen P, Lolk A, Gram LF, Kragh-Sorensen P: Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. Psychopharmacology (Berl). 1992;106(4):511-6. [Pubmed] ; Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. [Pubmed]
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com

REFERENCES

• Peppers MP: Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996 Jan-Feb;16(1):49-57. Pubmed
• Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. Pubmed
• Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. Pubmed
• Christensen P, Lolk A, Gram LF, Kragh-Sorensen P: Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. Psychopharmacology (Berl). 1992;106(4):511-6. Pubmed
• Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. Pubmed